PL3652178T3 - Bicykliczne związki ketonowe i sposoby ich stosowania - Google Patents

Bicykliczne związki ketonowe i sposoby ich stosowania

Info

Publication number: PL3652178T3
Authority: PL; Poland
Prior art keywords: methods; ketone compounds; bicyclic ketone; bicyclic; compounds
Prior art date: 2017-07-14

Application number

PL18740815.8T

Other languages

English (en)

Inventor

Snahel PATEL

Gregory Hamilton

Guiling Zhao

Huifen Chen

Blake DANIELS

Craig STIVALA

Original Assignee

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-07-14

Filing date

2018-07-12

Publication date

2024-05-06

2018-07-12 Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag

2024-05-06 Publication of PL3652178T3 publication Critical patent/PL3652178T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

PL18740815.8T 2017-07-14 2018-07-12 Bicykliczne związki ketonowe i sposoby ich stosowania PL3652178T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762532767P	2017-07-14	2017-07-14
PCT/EP2018/068998 WO2019012063A1 (en)	2017-07-14	2018-07-12	BICYCLIC KETONIC COMPOUNDS AND METHODS OF USE

Publications (1)

Publication Number	Publication Date
PL3652178T3 true PL3652178T3 (pl)	2024-05-06

Family

ID=62916677

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18740815.8T PL3652178T3 (pl)	2017-07-14	2018-07-12	Bicykliczne związki ketonowe i sposoby ich stosowania

Country Status (30)

Country	Link
US (3)	US11098058B2 (pl)
EP (2)	EP3652178B1 (pl)
JP (2)	JP7258843B2 (pl)
KR (2)	KR102664604B1 (pl)
CN (2)	CN110914271B (pl)
AR (1)	AR112274A1 (pl)
AU (3)	AU2018300043B2 (pl)
BR (1)	BR112020000771A2 (pl)
CA (2)	CA3185865A1 (pl)
CL (1)	CL2020000101A1 (pl)
CO (1)	CO2020000134A2 (pl)
CR (1)	CR20200002A (pl)
DK (1)	DK3652178T3 (pl)
ES (1)	ES2973661T3 (pl)
FI (1)	FI3652178T3 (pl)
HR (1)	HRP20240354T1 (pl)
HU (1)	HUE065793T2 (pl)
IL (2)	IL294961A (pl)
LT (1)	LT3652178T (pl)
MA (1)	MA49560B1 (pl)
PE (1)	PE20200793A1 (pl)
PH (1)	PH12020500105A1 (pl)
PL (1)	PL3652178T3 (pl)
PT (1)	PT3652178T (pl)
RS (1)	RS65308B1 (pl)
SG (1)	SG11202000333UA (pl)
SI (1)	SI3652178T1 (pl)
TW (1)	TWI805595B (pl)
UA (1)	UA125448C2 (pl)
WO (1)	WO2019012063A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201831478A (zh) *	2016-12-02	2018-09-01	瑞士商赫孚孟拉羅股份公司	雙環醯胺化合物及其使用方法
CA3185865A1 (en)	2017-07-14	2019-01-17	F. Hoffmann-La Roche Ag	Bicyclic ketone compounds and methods of use thereof
CR20200168A (es)	2017-10-31	2020-07-12	Hoffmann La Roche	Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CN113302193A (zh) *	2019-01-11	2021-08-24	豪夫迈·罗氏有限公司	双环吡咯并三唑酮化合物及其使用方法
WO2021198981A1 (en)	2020-04-01	2021-10-07	Janssen Biopharma, Inc.	Antiviral compounds and uses thereof
WO2021221444A1 (ko)	2020-04-27	2021-11-04	주식회사 오토텍바이오	Ubr 박스 도메인 리간드로의 화합물
KR20230165238A (ko) *	2021-04-02	2023-12-05	제넨테크, 인크.	비시클릭 케톤 화합물 제조 공정
WO2023039795A1 (zh) *	2021-09-16	2023-03-23	维泰瑞隆（北京）生物科技有限公司	Rip1激酶抑制剂及其用途
GEAP202516658A (en) *	2022-05-19	2025-03-25	Merck Sharp & Dohme Llc	Ripk1 inhibitors and methods of use
KR20260027251A (ko) *	2023-06-19	2026-02-27	에프. 호프만-라 로슈 아게	카이랄 피롤로 트리아졸 알코올의 제조 공정

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1620508A1 (de)	1965-07-23	1969-09-18	Thomae Gmbh Dr K	Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US3948903A (en)	1972-12-15	1976-04-06	Parke, Davis & Company	Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipide und Tenside in wässriger Phase
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en)	1986-04-30	1986-06-04	Fbc Ltd	Herbicides
US5004697A (en)	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en)	1990-04-23	1993-12-07	Alkermes, Inc.	Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en)	1990-04-23	1992-05-12	Alkermes, Inc.	Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
AU677216B2 (en)	1992-07-27	1997-04-17	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Targeting of liposomes to the blood-brain barrier
US6080772A (en)	1995-06-07	2000-06-27	Sugen, Inc.	Thiazole compounds and methods of modulating signal transduction
EP1007042A4 (en)	1997-06-13	2001-07-04	Sugen Inc	NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
US6653304B2 (en) *	2000-02-11	2003-11-25	Bristol-Myers Squibb Co.	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6514221B2 (en)	2000-07-27	2003-02-04	Brigham And Women's Hospital, Inc.	Blood-brain barrier opening
AU2001286930A1 (en)	2000-08-30	2002-03-13	The Board Of Trustees Of The Leland Stanford Junior University	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en)	2000-10-30	2006-04-25	Pain Therapeutics, Inc.	Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de)	2001-05-05	2008-01-24	Lts Lohmann Therapie-Systeme Ag	Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
EP2147679B1 (en)	2001-07-25	2014-06-25	Raptor Pharmaceutical, Inc.	Compositions for blood-brain barrier transport
US20030162695A1 (en)	2002-02-27	2003-08-28	Schatzberg Alan F.	Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2494700C (en)	2002-08-26	2011-06-28	Takeda Pharmaceutical Company Limited	Calcium receptor modulating compound and use thereof
US7220833B2 (en)	2002-12-03	2007-05-22	Thomas Nelson	Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
ATE410161T1 (de)	2003-05-02	2008-10-15	Elan Pharm Inc	4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
JP2007505142A (ja)	2003-09-10	2007-03-08	セダーズ−シナイメディカルセンター	血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
JP2008539220A (ja)	2005-04-26	2008-11-13	ファイザー・リミテッド	バソプレシンアンタゴニストとしてのトリアゾール誘導体
EP2083009A1 (de)	2008-01-22	2009-07-29	Grünenthal GmbH	Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en)	2009-03-02	2012-10-30	Roche Palo Alto Llc	Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh)	2009-03-05	2010-09-08	上海恒瑞医药有限公司	四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
TWI421252B (zh)	2009-07-09	2014-01-01	Irm Llc	用於治療寄生蟲疾病之化合物及組合物
KR20140096100A (ko)	2011-11-03	2014-08-04	에프. 호프만-라 로슈 아게	이환 피페라진 화합물
BR112014026176A2 (pt)	2012-05-22	2017-06-27	Hoffmann La Roche	dipiridilaminas substituídas e usos das mesmas
TWI498325B (zh)	2013-01-18	2015-09-01	Hoffmann La Roche	３－取代吡唑及其用途
TWI648273B (zh) *	2013-02-15	2019-01-21	英商葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之雜環醯胺類（三）
MY182082A (en)	2013-05-01	2021-01-18	Hoffmann La Roche	Biheteroaryl compounds and uses thereof
BR112015027381A8 (pt)	2013-05-01	2018-01-30	Hoffmann La Roche	pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos
SG11201600082VA (en)	2013-07-10	2016-02-26	Vertex Pharma	Fused piperidine amides as modulators of ion channels
MX2016008110A (es)	2013-12-20	2016-08-19	Hoffmann La Roche	Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
KR20160128428A (ko)	2014-03-26	2016-11-07	에프. 호프만-라 로슈 아게	오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물
AU2015304851A1 (en)	2014-08-21	2017-02-23	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as RIP1 kinase inhibitors as medicaments
WO2016128908A1 (en) *	2015-02-12	2016-08-18	Advinus Therapeutics Limited	Bicyclic compounds, compositions and medicinal applications thereof
CN107406462B (zh)	2015-03-09	2020-11-10	豪夫迈·罗氏有限公司	三环dlk抑制剂及其用途
CA3094197C (en)	2015-07-02	2023-02-28	F. Hoffmann-La Roche Ag	Bicyclic lactams and methods of use thereof
CN108602809B (zh)	2015-12-04	2022-09-30	戴纳立制药公司	异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
US10961258B2 (en)	2015-12-21	2021-03-30	Glaxosmithkline Intellectual Property Development Limited	Heterocyclic amides as kinase inhibitors
IL287136B2 (en)	2016-02-05	2023-09-01	Denali Therapeutics Inc	Receptor inhibitors - interacting with protein kinase 1
TW201831478A (zh)	2016-12-02	2018-09-01	瑞士商赫孚孟拉羅股份公司	雙環醯胺化合物及其使用方法
US11072607B2 (en)	2016-12-16	2021-07-27	Genentech, Inc.	Inhibitors of RIP1 kinase and methods of use thereof
CN110169087B (zh)	2017-01-05	2021-04-20	微软技术许可有限责任公司	重定向音频输出
CA3185865A1 (en)	2017-07-14	2019-01-17	F. Hoffmann-La Roche Ag	Bicyclic ketone compounds and methods of use thereof
CN111201229B (zh)	2017-10-11	2024-08-23	豪夫迈·罗氏有限公司	用作rip1激酶抑制剂的二环化合物
CR20200168A (es)	2017-10-31	2020-07-12	Hoffmann La Roche	Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos

2018
- 2018-07-12 CA CA3185865A patent/CA3185865A1/en active Pending
- 2018-07-12 KR KR1020207004030A patent/KR102664604B1/ko active Active
- 2018-07-12 US US16/034,207 patent/US11098058B2/en active Active
- 2018-07-12 PT PT187408158T patent/PT3652178T/pt unknown
- 2018-07-12 FI FIEP18740815.8T patent/FI3652178T3/fi active
- 2018-07-12 HU HUE18740815A patent/HUE065793T2/hu unknown
- 2018-07-12 CR CR20200002A patent/CR20200002A/es unknown
- 2018-07-12 CA CA3067944A patent/CA3067944C/en active Active
- 2018-07-12 UA UAA202000831A patent/UA125448C2/uk unknown
- 2018-07-12 CN CN201880046714.2A patent/CN110914271B/zh active Active
- 2018-07-12 ES ES18740815T patent/ES2973661T3/es active Active
- 2018-07-12 PL PL18740815.8T patent/PL3652178T3/pl unknown
- 2018-07-12 EP EP18740815.8A patent/EP3652178B1/en active Active
- 2018-07-12 KR KR1020247014915A patent/KR20240065201A/ko active Pending
- 2018-07-12 MA MA49560A patent/MA49560B1/fr unknown
- 2018-07-12 HR HRP20240354TT patent/HRP20240354T1/hr unknown
- 2018-07-12 TW TW107124048A patent/TWI805595B/zh active
- 2018-07-12 SI SI201831080T patent/SI3652178T1/sl unknown
- 2018-07-12 DK DK18740815.8T patent/DK3652178T3/da active
- 2018-07-12 PE PE2020000027A patent/PE20200793A1/es unknown
- 2018-07-12 IL IL294961A patent/IL294961A/en unknown
- 2018-07-12 JP JP2020501256A patent/JP7258843B2/ja active Active
- 2018-07-12 CN CN202411725301.0A patent/CN119613408A/zh active Pending
- 2018-07-12 AR ARP180101941 patent/AR112274A1/es active IP Right Grant
- 2018-07-12 LT LTEPPCT/EP2018/068998T patent/LT3652178T/lt unknown
- 2018-07-12 IL IL271981A patent/IL271981B/en unknown
- 2018-07-12 SG SG11202000333UA patent/SG11202000333UA/en unknown
- 2018-07-12 WO PCT/EP2018/068998 patent/WO2019012063A1/en not_active Ceased
- 2018-07-12 BR BR112020000771-4A patent/BR112020000771A2/pt unknown
- 2018-07-12 EP EP24152498.2A patent/EP4397309A3/en active Pending
- 2018-07-12 RS RS20240314A patent/RS65308B1/sr unknown
- 2018-07-12 AU AU2018300043A patent/AU2018300043B2/en active Active
2020
- 2020-01-08 CO CONC2020/0000134A patent/CO2020000134A2/es unknown
- 2020-01-13 CL CL2020000101A patent/CL2020000101A1/es unknown
- 2020-01-14 PH PH12020500105A patent/PH12020500105A1/en unknown
2021
- 2021-01-12 US US17/147,449 patent/US11834461B2/en active Active
- 2021-06-26 AU AU2021204369A patent/AU2021204369A1/en not_active Abandoned
2023
- 2023-04-05 JP JP2023061174A patent/JP7734163B2/ja active Active
- 2023-05-25 AU AU2023203292A patent/AU2023203292B2/en active Active
- 2023-11-21 US US18/516,014 patent/US20240300974A1/en active Pending

Also Published As

Publication number	Publication date
AU2023203292A1 (en)	2023-06-22
JP2023085449A (ja)	2023-06-20
AU2023203292B2 (en)	2025-01-30
EP3652178A1 (en)	2020-05-20
WO2019012063A1 (en)	2019-01-17
DK3652178T3 (da)	2024-03-25
SI3652178T1 (sl)	2024-05-31
EP4397309A3 (en)	2024-09-04
TW201920149A (zh)	2019-06-01
MA49560A (fr)	2020-05-20
EP4397309A2 (en)	2024-07-10
FI3652178T3 (fi)	2024-03-19
HRP20240354T1 (hr)	2024-06-07
JP2020526549A (ja)	2020-08-31
CA3185865A1 (en)	2019-01-17
HUE065793T2 (hu)	2024-06-28
BR112020000771A2 (pt)	2020-07-14
RU2020106375A3 (pl)	2022-03-25
US20240300974A1 (en)	2024-09-12
EP3652178B1 (en)	2024-01-24
CA3067944C (en)	2023-03-14
CR20200002A (es)	2020-02-10
US11098058B2 (en)	2021-08-24
US20210139504A1 (en)	2021-05-13
TWI805595B (zh)	2023-06-21
CN110914271B (zh)	2024-12-10
US11834461B2 (en)	2023-12-05
RU2020106375A (ru)	2021-08-16
MA49560B1 (fr)	2024-05-31
UA125448C2 (uk)	2022-03-09
CO2020000134A2 (es)	2020-01-17
AU2018300043B2 (en)	2021-04-01
KR102664604B1 (ko)	2024-05-14
IL271981B (en)	2022-09-01
CL2020000101A1 (es)	2020-07-17
AU2021204369A1 (en)	2021-07-29
PE20200793A1 (es)	2020-08-10
AU2018300043A1 (en)	2020-01-16
CN119613408A (zh)	2025-03-14
RS65308B1 (sr)	2024-04-30
CA3067944A1 (en)	2019-01-17
US20190100530A1 (en)	2019-04-04
JP7734163B2 (ja)	2025-09-04
PH12020500105A1 (en)	2020-11-09
NZ760749A (en)	2024-08-30
ES2973661T3 (es)	2024-06-21
SG11202000333UA (en)	2020-02-27
IL294961A (en)	2022-09-01
KR20240065201A (ko)	2024-05-14
CN110914271A (zh)	2020-03-24
IL271981A (en)	2020-02-27
JP7258843B2 (ja)	2023-04-17
LT3652178T (lt)	2024-04-10
AR112274A1 (es)	2019-10-09
KR20200030558A (ko)	2020-03-20
PT3652178T (pt)	2024-03-18

Publication	Publication Date	Title
IL274391B (en)	2022-02-01	Bicyclic lactams and methods of using them
IL271981A (en)	2020-02-27	Bicyclic ketone compounds and methods of using them
ZA201905677B (en)	2022-12-21	Glycan-interacting compounds and methods of use
HUE068842T2 (hu)	2025-01-28	Vegyületek és alkalmazási eljárásaik
IL261625B (en)	2021-08-31	Inhibitors of menin-mll in bridged cycles and methods of use
IL265800A (en)	2019-06-30	Anti-lag-3 antibodies and methods of using them
SG11201803213XA (en)	2018-05-30	Glycan-interacting compounds and methods of use
EP3377070A4 (en)	2019-07-10	COMPOUNDS AND METHOD FOR THEIR USE
HUE061672T2 (hu)	2023-08-28	Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
HUE073475T2 (hu)	2026-01-28	C1s elleni antitestek és alkalmazási eljárásaik
PL3089971T3 (pl)	2021-01-25	Związki i sposoby ich zastosowania
GB201609786D0 (en)	2016-07-20	Compounds and method of use
IL283387A (en)	2021-07-29	Diarylhydantoin compounds and methods of use thereof
IL267671A (en)	2019-08-29	Pyrazolopyrimidine compounds and methods of their use
GB201514760D0 (en)	2015-09-30	Compounds and method of use
IL265955A (en)	2019-05-30	Therapeutic compounds and methods of using them
IL277963A (en)	2020-11-30	Bicyclic carboxamides and methods of using them
ZA201606450B (en)	2019-12-18	Compounds and their methods of use
GB2565019B (en)	2020-12-09	Method of manufacture of ladder polybenzodifurans and use thereof
GB201403697D0 (en)	2014-04-16	Compounds and methods of use
CA3281817A1 (en)	2026-03-02	Compounds and their methods of use
HK40016047A (en)	2020-09-04	Fused hetero-hetero bicyclic compounds and methods of use thereof
HK40017698A (en)	2020-09-25	Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
HK40007173A (en)	2020-05-29	Glycan-interacting compounds and methods of use
HK40009339A (en)	2020-06-26	Amino-pyrrolopyrimidinone compounds and methods of use thereof